Company Information

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Kitov’s pipeline currently features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. Lowering development risk and cost through streamlined regulatory approval of novel late-stage therapeutics, Kitov delivers rapid ROI while making a meaningful impact on people’s lives. 

Read More

Price Data
NASDAQKTOV
Recent News
May 1, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today filed a 6-K with an update on the ongoing Israeli Securities Authority Investigation....

Apr 3, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver...

Mar 27, 2017

Combined treatment of TyrNovo's NT219 with targeted cancer drugs overcame acquired resistance of colon, lung, and head-and-neck cancers in PDX models Kitov Pharmaceuticals (NASDAQ and TASE: KTOV),...

More >


print email